Beam Therapeutics Inc.(BEAM)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
BEAM | 2.57 B | - | -94.20% | -55.45% | -$0.68 | -8.18% | 0.23x | 0.00% | $38.26 | $20.23 |
VRTX | 130.44 B | 29.80x | 12.50% | 35.00% | $17.27 | 23.54% | 0.10x | 0.00% | $560.25 | $403.16 |
MRNA | 96.65 B | - | 2.10% | -141.43% | -$7.98 | -39.00% | 0.19x | 0.00% | $243.98 | $22.28 |
ALNY | 30.87 B | 38.91x | 66.90% | 16.13% | $5.93 | 96.56% | 2.21x | 0.00% | $490.05 | $197.81 |
CRSP | 4.82 B | - | 1041.40% | 0.00% | -$4.74 | -26.10% | 0.45x | 0.00% | $75.06 | $44.12 |
NTLA | 1.66 B | - | -46.20% | 0.00% | -$3.35 | -55.44% | 0.10x | 0.00% | $27.86 | $7.95 |
Peer Valuation & Performance Analysis
Peer group analysis for Beam Therapeutics Inc. (BEAM) compared to its primary competitors (including VRTX, MRNA, ALNY) reveals distinct metrics. BEAM trades at a valuation discount relative to its competitors, with a P/E ratio of -36.7x versus the peer average of 4.9x (representing a 854% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, BEAM's revenue growth of -94.2% lags behind the peer average of 215.3%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of -55.5% is below the peer average of -18.1%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• BEAM ranks #0 in P/E ratio, #5 in revenue growth, and #4 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $24.00 | $25.06 | $23.61 | $24.93 | 1,469,040 | +3.06% |
| 2026-10-19 | $23.89 | $24.38 | $23.50 | $24.19 | 1,316,500 | +3.07% |
| 2026-10-16 | $24.56 | $24.56 | $23.16 | $23.47 | 1,645,800 | -5.10% |
| 2026-10-15 | $23.51 | $24.98 | $23.20 | $24.73 | 1,779,900 | +4.57% |
| 2026-10-14 | $24.13 | $24.26 | $23.28 | $23.65 | 1,660,700 | -3.19% |
| 2026-10-13 | $24.88 | $24.93 | $24.08 | $24.43 | 1,667,900 | -2.79% |
| 2026-10-12 | $25.63 | $26.09 | $24.93 | $25.13 | 1,412,800 | -2.22% |
| 2026-10-09 | $24.72 | $26.23 | $24.55 | $25.70 | 1,800,200 | +4.47% |
| 2026-10-08 | $24.26 | $24.69 | $23.91 | $24.60 | 2,425,900 | -0.69% |
| 2026-10-07 | $24.64 | $25.37 | $24.45 | $24.77 | 2,342,400 | -1.82% |
| 2026-10-06 | $26.80 | $26.94 | $24.86 | $25.23 | 2,516,700 | -1.71% |
| 2026-10-05 | $24.48 | $26.04 | $23.83 | $25.67 | 1,999,200 | +4.78% |
| 2026-10-02 | $25.00 | $25.48 | $24.21 | $24.50 | 1,497,500 | +0.45% |
| 2026-10-01 | $24.24 | $24.98 | $23.95 | $24.39 | 1,693,300 | -0.25% |
| 2026-09-30 | $24.79 | $25.20 | $24.41 | $24.45 | 1,555,600 | -0.29% |
Explore More Analysis for BEAM
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.